Evidence map›Paper›PMID 25667608›Full record

ArticleExperimental and therapeutic medicine2015

Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Márcio G Soeiro-DE-Souza, Vasco Videira Dias, Giovanni Missio, Vicent Balanzá-Martinez, Leandro Valiengo, André F Carvalho, Ricardo Alberto Moreno

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Márcio G Soeiro-DE-SouzaMood Disorders Unit (GRUDA), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
Vasco Videira DiasMood Disorders Unit (GRUDA), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
Giovanni MissioMood Disorders Unit (GRUDA), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
Vicent Balanzá-MartinezUniversity Hospital Doctor Peset and Section of Psychiatry, University of Valencia, Valencia, Spain ; CIBER Mental Health (CIBERSAM), Carlos III Health Institute, Madrid, Spain.
Leandro ValiengoLaboratory of Neuroscience (LIM27), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
André F CarvalhoPsychiatry Research Group and Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Brazil.
Ricardo Alberto MorenoMood Disorders Unit (GRUDA), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal do Ceará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present review was to discuss the following aspects of treatment with quetiapine in psychiatric disorders: i) Neurocognition and functional recovery in bipolar disorder (BD); ii) neuroprotective profile in different models; and iii) potential off-label indications. A PubMed search was conducted of articles published in English between 2000 and 2012 on quetiapine, cross-referenced with the terms 'anxiety', 'attention deficit disorder', 'borderline personality disorder', 'dementia', 'insomnia', 'major depressive disorder' (MDD), 'obsessive-compulsive disorder', 'post-traumatic stress disorder', 'remission', 'cognition', 'neurobiology', 'neuroprotection', 'efficacy' and 'effectiveness'. Articles were selected from meta-analyses, randomized clinical trials and open trials, and the results were summarized. Quetiapine, when studied in off-label conditions, has shown efficacy as a monotherapy in MDD and general anxiety disorder. Quetiapine also appears to exhibit a small beneficial effect in dementia. The review of other conditions was affected by methodological limitations that precluded any definitive conclusions on the efficacy or safety of quetiapine. Overall, the present review shows evidence supporting a potential role for quetiapine in improving cognition, functional recovery and negative symptoms in a cost-effective manner in BD. These benefits of quetiapine are potentially associated with its well-described neuroprotective effects; however, further studies are clearly warranted.

Indexed as

antipsychoticsdepressionneurocognitionneuroprotectionpsychopharmacologyquetiapine

Identifiers

PMID25667608
PMCPMC4316978
OpenAlexW2136826032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.